Paid Bashers use anonymity and they’re cheap as chips to hire. So, it’s no surprise some companies, or individuals, hire them to do their dirty work in getting ahead of the competition.
With the growth of social media, their number and level of influence have only grown. There is very little anyone can do, to decipher someone else’s motives or who’s putting bread on their table — so the best way to deal with these posters is to be mindful of their patterns and keeping an eye if a particular chat room patron is grinding his/her axe a bit too much against one specific company or individual.
I think a lot of the delay in contracts and manufacturing has been waiting for ISO13485 to be passed,so Avacta can have their name on Affidx and not Mologic.
Mologic would have known for months Gates foundation were buying them and it could of been that Gates foundation wouldn’t want Mologic’s name on another companies test product. 14th July ISO13485 passed 19th July the following Monday Gates foundation news announced.
I wouldn’t be surprised this is why on the FIND database has not been updated to show Avacta's LFT as being on the market it passed CE under Mologic
Successful first data transfer of detection of SARS-CoV-2 via Microtox® PD units has completed with unidentified clients from installed units in undisclosed locations (under strict conditions of NDA's).
We are now 12 months since RNS below could be news soon on progress of this therapy.
29 July 2020 Avacta Group plc ("Avacta" or "the Group" or "the Company")
Expansion of Partnership with Daewoong Pharmaceutical to Include COVID-19 Neutralising Affimer Therapy Collaboration to develop stem cell therapies for COVID-19 and future pandemic diseases Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. (KSX: 069620) and AffyXell Therapeutics, the joint venture established in South Korea by the two companies, to develop stem cell treatments incorporating Avacta's neutralising Affimer therapy for the treatment of seriously ill patients with COVID-19 and to also prepare to rapidly develop similar therapies for future global pandemics. Respiratory diseases such as COVID-19 can cause serious damage to the lungs as a consequence of over-activation of the patient's immune system, resulting in cytokine release syndrome that can potentially lead to multiple organ failure and death. Stem cell therapies offer a very promising approach to repair the damage to lung tissues in these pulmonary diseases by controlling the immune balance. AffyXell Therapeutics, the next-generation cell and gene therapy joint venture between Avacta and Daewoong Pharmaceutical, is developing a novel class of mesenchymal stem cell (MSC) treatments that are engineered to also produce Affimer therapies in the patient at the site of action. The expansion of the agreement between Avacta, Daewoong Pharmaceutical and AffyXell announced today extends the scope of the partnership to include Affimer molecules that target viruses, such as coronaviruses, in order to develop therapies that repair the lung damage caused by COVID-19 whilst also producing neutralising Affimer molecules to prevent the progression of the disease. AffyXell will engineer mesenchymal stem cells to express SARS-COV-2 neutralising Affimer molecules in order to develop treatments for seriously ill COVID-19 patients, and will also prepare for rapid development of next-generation stem cell therapies for future infectious respiratory disease outbreaks.